Advancing Extracellular Vesicle Therapeutics Into Clinical Trials For Owing to their natural origin and biocompatibility, extracellular vesicles (evs) are being recognized as next generation vehicles for targeted drug delivery. We describe here the use of extracellular vesicles (evs) as rna and protein delivery vehicles. we outline the advantages and disadvantage to using evs as delivery vehicles and posit that evs will emerge as a bona fide next generation gene and cell therapy delivery approach.
Pioneering Next Generation Extracellular Vesicle Therapeutics News Evs have gained attention as novel delivery systems for protein and peptide therapeutics owing to their small size, biocompatibility, intrinsic targeting capabilities, lower immunogenicity, and ability to protect cargo from enzymatic degradation. From their humble discovery as cellular debris to cementing their natural capacity to transfer functional molecules between cells, the long winded journey of extracellular vesicles (evs) now stands at the precipice as a next generation cell free therapeutic tool to revolutionize modern day medicine. Loughborough university scientists are discovering how their potential can be harnessed to manufacture next generation therapeutic platforms to treat challenging diseases such as cancer and osteoporosis. Extracellular vesicles (evs), among other carriers, have emerged as highly promising candidates for next generation therapeutics and diagnostic tools.
The Extracellular Vesicle Landscape From Biomarker Discovery To Loughborough university scientists are discovering how their potential can be harnessed to manufacture next generation therapeutic platforms to treat challenging diseases such as cancer and osteoporosis. Extracellular vesicles (evs), among other carriers, have emerged as highly promising candidates for next generation therapeutics and diagnostic tools. Associate professor joy wolfram leads a nanomedicine and extracellular vesicle research program with the goal of developing innovative approaches that bring the next generation of treatments and diagnostics directly to the clinic. Morris and colleagues describe and compile key studies developing extracellular vesicles (evs) as therapeutic rna delivery vehicles. we outline the approaches to engineering evs and the advantages and disadvantages of using evs as delivery vehicles as a next generation gene and cell therapy delivery approach. The authors mark new avenues for future work related to evs, with the goal to improve ev based therapeutic strategies. importantly, current limitations of ev utility are also discussed, such as manufacturing, scalability, molecular characterization and targeted delivery. This paper discusses the state of the art regulatory knowledge to date on ev based diagnostics and medicinal products, highlighting further research and global regulatory needs for the safe and reliable implementation of bioengineered evs as diagnostic and therapeutic tools in clinical settings.
A Panorama Of Extracellular Vesicle Applications From Biomarker Associate professor joy wolfram leads a nanomedicine and extracellular vesicle research program with the goal of developing innovative approaches that bring the next generation of treatments and diagnostics directly to the clinic. Morris and colleagues describe and compile key studies developing extracellular vesicles (evs) as therapeutic rna delivery vehicles. we outline the approaches to engineering evs and the advantages and disadvantages of using evs as delivery vehicles as a next generation gene and cell therapy delivery approach. The authors mark new avenues for future work related to evs, with the goal to improve ev based therapeutic strategies. importantly, current limitations of ev utility are also discussed, such as manufacturing, scalability, molecular characterization and targeted delivery. This paper discusses the state of the art regulatory knowledge to date on ev based diagnostics and medicinal products, highlighting further research and global regulatory needs for the safe and reliable implementation of bioengineered evs as diagnostic and therapeutic tools in clinical settings.
Comments are closed.